Dimerix Ltd has released a press release.
Approval received for Paediatric Investigation Plan from EMA
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Dimerix
- Dimerix confirms Phase 3 study design appropriate for China
- Prospectus
- Dimerix Announces Update on Successful Capital Raise
- Rights Issue Prospectus
- Reinstatement to Official Quotation
Later from Dimerix
- DMX-200 FSGS PH3 Kidney Trial Part 1 Outcome set for Q1 CY24
- Successful Completion of 2nd DSMB Review of FSGS Trial
- Dimerix Receives $8.9M R&D Tax Incentive Rebate
- Regulatory Approval received in Malaysia for ACTION3 Study
- FDA Approves Qytovra Brand Name
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix